Search results
Results From The WOW.Com Content Network
p-Phenylenediamine (PPD) is an organic compound with the formula C 6 H 4 (NH 2) 2. This derivative of aniline is a white solid, but samples can darken due to air oxidation. [ 1 ] It is mainly used as a component of engineering polymers and composites like kevlar .
Agents, mixtures and exposure circumstances that do not fall into any other group are also placed in this category. The IARC Monographs on which this list is based assess the hazard linked to the agents, they do not assess the cancer risk of the agents. [1] The list is up-to-date as of January 2024. [2]
6PPD is an organic chemical widely used as stabilising additive (or antidegradant) in rubbers, such as NR, SBR and BR; all of which are common in vehicle tires. [1] Although it is an effective antioxidant it is primarily used because of its excellent antiozonant performance.
Pages for logged out editors learn more. Contributions; Talk; Para-phenylenediamine
Eftilagimod alpha (INN; [1] development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep.Efti is a soluble version of the immune checkpoint molecule LAG-3.
It is a white solid at room temperature. It is one of two precursors used to make Kevlar, the other being p-phenylenediamine. TCL is used as a key component in performance polymers and aramid fibers, where it imparts flame resistance, chemical resistance, temperature stability, light weight, and very high strength.
o-Phenylenediamine (OPD) is an organic compound with the formula C 6 H 4 (NH 2) 2. This aromatic diamine is an important precursor to many heterocyclic compounds. OPD is a white compound although samples appear darker owing to oxidation by air. It is isomeric with m-phenylenediamine and p-phenylenediamine.
Blinatumomab linking a T cell to a malignant B cell.. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.